Total tau (T-tau), phosphorylated tau (p-Tau) and Beta-Amyloid 1–42 (AB42) in Cerebrospinal Fluid (CSF) are useful biomarkers in neurodegenerative diseases. The aim of the study was to investigate the role of these and other CSF biomarkers (T-tau, p-Tau, AB42, S100B and NSE), during hypoxia-reoxygenation in a newborn pig model.
Thirty newborn pigs were included in a study of moderate or severe hypoxia. The moderate hypoxia group (n = 12) was exposed to global hypoxia (8% O2) until Base excess (BE) reached -15 mmol/l. The pigs in the group exposed to severe hypoxia (n = 12) received 8% O2 until BE reached -20 mmol/l or mean Blood Pressure fell below 20 mm Hg, The control group (n = 6) was kept at room air. For all treatments, the CSF was collected at 9.5 hours after the intervention.
The level of AB42 in CSF was significantly lower in the pigs exposed to severe hypoxia compared with the control group, 922(SD +/-445)pg/ml versus. 1290(SD +/-143) pg/ml (p<0.05), respectively. Further, a non-significant reduction of AB42 was observed in the group exposed to moderate hypoxia T-tau and p-Tau revealed no significant differences between the intervention groups and the control group, however a significantly higher level of S100B was seen in the CSF of pigs receiving hypoxia in comparison to the level in the control group. Further on, there was a moderate negative correlation between the levels of AB42 and S100B in CSF, as well as a moderate negative correlation between Lactate in blood at end of hypoxia and AB42 in CSF.
This is the first study to our knowledge that demonstrated a significant drop in AB42 in CSF after neonatal hypoxia. Whether or not this has an etiological basis for adult neurodegenerative disorders needs to be studied with additional experiments and epidemiological studies. AB42 and S100B are significantly changed in neonatal pigs subjected to hypoxia compared to controls and thus may be valuable biomarkers of perinatal asphyxia.
Citation: Benterud T, Pankratov L, Solberg R, Bolstad N, Skinningsrud A, Baumbusch L, et al. (2015) Perinatal Asphyxia May Influence the Level of Beta-Amyloid (1-42) in Cerebrospinal Fluid: An Experimental Study on Newborn Pigs. PLoS ONE 10(10): e0140966. https://doi.org/10.1371/journal.pone.0140966
Editor: Tonse Raju, NIH, UNITED STATES
Received: March 13, 2015; Accepted: August 20, 2015; Published: October 26, 2015
Copyright: © 2015 Benterud et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited
Data Availability: All relevant data are within the paper and its Supporting Information files.
Funding: This work was supported by funding from Helse Sør-Øst (South and Eastern Norway Regional Health Authority); Source number: 6051. Project number: 39570. Roche Diagnostics supported the study with ELISA kits for investigating S100B in CSF and blood. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing interests: Roche Diagnostics supported the study with ELISA kits for investigating S100B in CSF and blood. This does not alter the authors' adherence to PLOS ONE policies on sharing data and materials.
Intrapartum events are among the most common causes of neonatal death with more than 800,000 annual cases worldwide .
Even though the majority of the children exposed to severe perinatal asphyxia will survive, many of them will suffer from long-term sequelae, such as cerebral palsy and cognitive deficits.
In severe cases, perinatal asphyxia may lead to Hypoxic-Ischemic Encephalopathy (HIE), which may cause permanent neurological damage.
Proteins, such as S100B and Neuron specific Enolase (NSE), released into the cerebrospinal fluid (CSF) during neuronal injury, might be useful as biomarkers in reflecting disease severity and predicting the clinical outcome after perinatal asphyxia .
We addressed the question whether total-tau (T-tau), phospho-Tau (p-Tau) and Beta-Amyloid 1–42 (AB42), biomarkers of adult neurodegenerative disorders, could serve as markers of perinatal asphyxia [3,4,5].
In pediatric populations altered T-tau levels in CSF have been found in patients with brain tumors  and West syndrome (Infantile spasms) . Magnoni et al.(2012) found that T-tau in the brain extracellular space was increased and negatively correlated with Beta-Amyloid levels in the extracellular space after traumatic brain injury and that T-tau may be helpful when predicting the clinical outcome .
Few, if any, experiments have been conducted to investigate if there is an association between asphyxia in the neonates and the levels of these markers.
In addition to T-tau, p-Tau and AB42, we also addressed the question of how NSE and S100B were affected in our model of neonatal hypoxia-reoxygenation.
The objective was to determine a possible correlation between the levels of CSF T-tau, p-Tau, AB42, S100B and NSE after hypoxia-reoxygenation in the newborn pig and establish a possible association between perinatal hypoxia-reoxygenation and any of these markers.
Materials and Methods
Thirty newborn pigs, age12–36 hours, Hb > 5g/dl and in good general condition were included in the study.
The pigs were given fentanyl 25microg/kg, midazolam 1.0mg/kg and pentobarbitone 20mg/kg intravenously as bolus injections for induction of anaesthesia before they were intubated and placed on their backs and washed for sterile procedures. Anaesthesia was maintained by a continuous infusion of fentanyl (50 microg/kg/h) and midazolam (0.25 mg/kg/h; IVAC P2000 infusion pump). When necessary, a bolus of fentanyl (10 microg/kg) and midazolam (1 mg/kg) were administered (need for medication being defined as shivering, increase in blood pressure and/or pulse and increased tone assessed by passive movements of the limbs). Pentobarbitone (2.5 mg/kg) was a few times added if there was increased muscular tone that did not respond to fentanyl or midazolam. A continuous iv. infusion, Salidex: saline 0.3% and glucose 3.5%, 10 ml/kg/h was given until start of hypoxia. From 15 min after end of hypoxia the infusion was continued at 5 ml/kg/h.
The pigs were ventilated with a pressure-controlled ventilator (Babylog 8000+; Drägerwerk, Lübeck, Germany) IMV mode, humidification by Fisher and Paykel MR730, 39°C. Normoventilation (arterial carbon dioxide tension (PaCO2) 4.5–6.0 kPa) was achieved by adjusting the peak inspiratory pressure or ventilatory rate.
The left jugular vein was cannulated with an arterial canula with FloSwitch (20G/1,10mm x 45mm. B.D. Faraday Road, Swindon, UK), and the right carotic artery was cannulated using a venflon (BD Venflon Pro, 22GA, 0,9mm x 25mm. Becton Dickinson Infusion Therapy AB, Helsingborg, Sweden). Both procedures were conducted under sterile conditions, and the cannulas were sutured to the skin. The animals were thereafter placed in a prone position for the rest of the experiment. Rectal temperature was maintained between 38.5 and 39.5°C with a heating blanket and a radiant heating lamp. Mean arterial blood pressure (MABP) was measured continuously in the right carotic artery using BioPac systems MP150-CE.
Twelve pigs were included in each experimental group and six pigs were in the control group. After 1 hour of stabilization the pigs in the intervention groups went through global hypoxia and reoxygenation with air.
The pigs in the first experimental group were exposed to global hypoxia (8% O2 in Nitrogen) until Base Excess (BE) reached -15 mmol/l (moderate hypoxia). The animals in the second experimental group (severe hypoxia) were exposed to 8% O2 until BE reached -20 mmol/l and/ or mean blood pressure fell below 20 mmHg. During hypoxia, CO2 was added, aiming at a PaCO2 8.0–9.5 kPa, to imitate perinatal asphyxia. After the hypoxic challenge the pigs were reoxygenated with air and observed for 9.5 hours. The pigs in the control group were not exposed to hypoxia. Invasive blood pressure, EEG and ECG were measured continuously. The experiments were performed under Midazolam and Fentanyl anaesthesia, and all efforts were made to minimize suffering. Between 0.5 and 1.0 ml of CSF was collected via lumbar puncture with a 22G spinal needle from each pig at the end of the study and frozen at -70°C for further analysis (Fig 1). Blood for measuring Hb and S100B was collected before hypoxia and at the end of the study and frozen at -70°C. In addition arterial blood gases were collected at several time points throughout the experiment
Twelve pigs were included in each experimental group and six pigs in the control group. The pigs in the first experimental group were exposed to global hypoxia (8% O2 in Nitrogen) until Base Excess (BE) reached -15 mmol/l (moderate hypoxia). The animals in the second experimental group (severe hypoxia) were exposed to 8% O2 until BE reached -20 mmol/l and/ or mean blood pressure fell below 20 mmHg. Thereafter the pigs were reoxygenated with air for 9.5 hours. CSF was collected 9.5 hours after end of hypoxia.
Method of sacrifice
After 9.5 hours of reoxygenation the pigs were subjected to euthanasia with an overdose of Pentobarbitone (150mg/kg).
The Norwegian Council for Animal Research approved the experimental protocol (approval number 4630). The animals were cared for and handled in accordance with the European Guidelines for the use of experimental animals by researchers who have been certified by the Federation of European Laboratory Animals Science Association (FELASA).
CSF was sampled from 30 pigs via lumbar puncture. The quality of the CSF of three pigs was insufficient; therefore these were not included in the study. The samples were stored at -70°C until further analyzes. Then they were thawed, mixed and diluted and analyzed according to the manufacturers' instructions. For T-tau, p-Tau and AB42 ELISA kits were applied. (Innotest hTau Ag, Innotest Phospho-Tau (181P) and Innotest Beta-Amyloid; all Innogenetics, Gent, Belgium). S100B was measured using an electrochemiluminescent immunometric assay (ECLIA) on Cobas e 601 immunoassay platform (Roche Diagnostics,Mannheim,Germany). S100B cannot be assayed in EDTA-plasma, and thus serum was derived from the originally collected EDTA-plasma by adding 20 microL 2M CaCl2 to 1 mL sample. The samples were left to clot for 1 hour and centrifuged at 2500g for 15 minutes prior to assay of S100B. Neuron-specific Enolase was measured using the Kryptor NSE assay (Thermo Fischer Scientific B.R.A.H.M.S, Asnières, France), an automated homogenous immunometric assay based on the Time Resolved Amplified Cryptate Emission (TRACE) technology .
Brain tissue from hippocampus was homogenized in 5M guanidine HCl buffer with protease inhibitor and PMSF using Omnitip (Omni International USA). Homogenate was diluted with sample dilution buffer to 1:50 and 1:200. Final guanidine HCl concentrations were below 0.1 m. Sample duplicates were run on AB42 specific sandwich colorimetric ELISAs following the protocol of the manufacturer (BioSource, Camarillo, CA, USA). Optical densities at 450 nm of each well were read on a Multiscan Ascent (Thermo Scientific, MA, USA) and sample Aβ42 concentrations were determined by comparison with the AB42 standard curves.
Four microm thick sections, which had been stored in 4% formaldehyde, were deparaffinized and rehydrated. The sections kept in citrate buffer, were heated in microwave for 15 min. The sections were then incubated with Formic acid 80% for 10 minutes, prior to blocking in a Peroxidase Block, 3% H2O2 for 10 minutes.
Following brief washes with Blocking buffer (5% goat serum, 5% BSA) for 30 minutes, the sections were incubated with Primary Antibody 6E10 (1:1000), a mouse monoclonal antibody, APP (Biolegend, MA, USA), and incubated over night at -4°C. The next day the slices were incubated with ImmPRESS (anti-mouse IgG, Vector Laboratories, CA, USA) for 30 minutes. For visualization DAB plus Peroxidase Substrate (Vector Laboratories, CA, USA) Kit were used.
Expression analysis of Amyloid Protein Precursor (APP) from Hippocampus
Total RNA was extracted from tissue samples using the EZNA Total RNA Kit II (Omega Bio-Tek, Inc, Norcross GA, USA) according to manufacturers’ instructions.
Purified RNA was quantified using NanoDrop ND-1000 (NanoDrop Technologies, Delaware, USA) and 2 microg were reverse transcribed into cDNA with the High capacity cDNA Reverse Transcription kit (Applied Biosystems, Life Tech, CA, USA).
Primers were designed using Primer Express 3.0 Software (Applied Biosystems, USA).
Primer sequence: Forward: 5-´ CAGATCCGATCCCAGGTTATGA-3´.
Primer sequence: Reverse: 5-´AGCAGGAACGTTGTAGAGCAGG-3´.
A tenfold dilution of each primer showed efficiency of between 90% and 110%.
Amplification was performed for both target genes and reference gene P0 in a ViiA 7 Real Time PCR System, universal settings (Applied Biosystems, Life Tech, CA, USA).
An amount of 50 ng of each sample was run in duplicate with 400 nmol/l primers and Power SYBR Green Master Mix (Applied Biosystems, Warrington, UK).
Data were analyzed by the comparative Ct method (Delta-delta Ct method).
The data were statistically analyzed using the Kruskal-Wallis test and Mann-Whitney U test for variables with non-normal distributions, and independent samples t test when the distribution was normal. Levene´s test for equality of variance was performed before performing the t-test. If Levene´s test documented a significant variance difference between the compared groups, a t-test assuming different variances was performed. Otherwise, a t-test assuming equal variance was performed.
The biomarkers S100B and NSE were log-transformed to obtain a normal distribution.
Pearson´s correlation was used for calculation of the correlation between the log-values of NSE and S100B and between Lactate andAB42. The statistical analyses were performed by SPSS Statistics 19.0 (SPSS Inc., Chicago, IL, USA).
Comparing the two treatment groups of either moderate or severe hypoxia and the control group, there were no significant differences in weight, hemoglobin level, age, BE, PaCO2 or glucose level at start (Table 1). Table 2 describes the arterial blood gases, lactate and glucose taken at 5 different time points during the experiment. For one of the pigs in the group exposed to moderate hypoxia the BP fell below 20mmHg before reaching the predestined value of BE = -15mmol/l, (BE = -11mmol/l).
At the end of hypoxia and 30 minutes after end of hypoxia there were significant differences between both intervention groups and the control group regarding the levels of BE, pH, lactate and glucose (p<0.05). Until 90 minutes after end of hypoxia there were still significant differences in all 4 parameters between the group exposed to severe hypoxia and the control group and BE and lactate remained significantly different until 120 minutes after end of hypoxia (p<0.05). Blood gases taken at later time points of recovery showed no significant differences between the groups.
Because of insufficient quality of CSF from 3 pigs, there were 5 pigs in the control group, 10 pigs in the group exposed to moderate hypoxia and 12 pigs in the group exposed to severe hypoxia. Fig 2 describes the level of AB42 in CSF for each group.
AB42 was significantly lower in the group exposed to severe hypoxia * compared with the control group, 922 (SD +/-445) pg/ml vs. 1290 (SD +/-143) pg/ml, p<0.05. Mean difference was 368 (95% CI: 61–675). The concentration of AB42 in the group exposed to moderate asphyxia was 1059 (SD+/-75) pg/mg, p = 0.07, when compared with the control group.
There was a slight correlation between AB42 and LogS100B in CSF as well as AB42 in CSF and arterial Lactate (Fig 3A and 3B).
(A): Correlation between Log S100B and AB42 in CSF. There was a moderate negative correlation between LogS100B and AB42 in CSF, R = -0.418, p<0.05. (B): Correlation between Arterial Lactate and AB42 in CSF. Arterial Lactate at end of Hypoxia had a moderate negative correlation with AB42, R = -0.419, p = 0.03
We measured the levels of S100B in CSF and serum and the concentration of NSE in CSF (Fig 4A and 4B).
(A) shows the Log-values of S100B in CSF for both intervention groups and the Control group, Log-S100B was significantly higher in the group exposed to hypoxia than in the control group, 1.0 (SD +/-0.3) pg/ml vs. 1.4 (SD +/-0.4) pg/ml, p<0.05. Mean difference was 0.4 (95% CI: 0.2–0.9). (B) depicts the Delta-Value from End of Hypoxia to End of experiment, p = 0.05. There was no difference between the group exposed to moderate vs. severe hypoxia regarding the levels of S100B, neither in CSF nor in blood, therefore we decided to combine both hypoxia groups into one intervention group.
In spite of no significant difference of NSE in CSF between the hypoxia and control groups, p = 0.11, we found a strong correlation between the levels of NSE and S100B in CSF, (Fig 5).
Fig 5 describes the correlation between the logarithmic values of NSE and S100B in CSF. It was a high correlation between logNSE and logS100B measured in CSF at the end of the experiment, R = 0.86, p<0.001. The values are depicted as log-values because there was a relatively wide range in the concentration of NSE and S100B.
There were no differences between the intervention groups and the control group for T-tau and p-Tau in CSF.
AB42 could not be detected by ELISA in brain tissue homogenates and aggregated AB42 were not observed in any part of the brains by immunohistochemistry or in any of the slices and any of the animals examined.
The groups revealed no differences the gene expression of Amyloidal Precursor Protein in Hippocampus or Cortex.
The newborn pigs exposed to severe hypoxia revealed significantly lower levels of AB42 in CSF compared to the control group. To our knowledge the present study is the first to report a significant reduction in the level of AB42 in CSF and hypoxia-reoxygenation in a neonatal model.
A similar tendency was observed, although not significant, for those exposed to moderate hypoxia.
In accordance with the amyloid hypothesis decreased AB42 in CSF is supposed to be the first biomarker change to occur in AD [12,13]. A possible explanation for the absent T-tau and p-Tau changes in our experiment might be that the available limited time of 9.5 hours in our model is too short to develop tau changes. With longer observation time one might expect increased T-tau, an unspecific marker of neuronal injury.
AB42 and its protein precursor, Amyloid Beta protein precursor (B-APP) have played a central role in research on AD. However, the function of B-APP and AB in the nervous system is controversial.
B-APP-knockout mice show severe behavioral deficits, possibly indicating that B-APP has important physiological functions in the nervous system.
In the prodromal and preclinical stages of AD the level of AB42 in CSF is reduced  and we found a similar pattern in the present neonatal hypoxia-reoxygenation model. In AD, the level of soluble AB42 correlates with synaptic changes and disease severity , indicating an imbalance between production and clearance of AB42.
B, resulting in accumulation of toxic AB aggregates, neuroinflammation and neuronal cell death .
AB are known to self-assemble into oligomers, which are thought to be an important source of toxicity by damaging the neurons .
Lambert et al.(1998) presented in a mouse model that neurotoxins comprising oligomers of AB42 could kill neurons in hippocampus . AB induces liposome fusion in vitro, which may suggest that AB in a non-fibrillar form may play a role in the progression of AD by directly disturbing the plasma membrane of neurons and altering its property . Pillot. et al (1999) were able to show that in a primary culture from cortical neurons, AB could induce neurotoxicity via an apoptotic pathway .
In accordance to other studies we found that S100B in CSF was significantly higher for those exposed to hypoxia [21, 22]. However, a significant moderate negative correlation between AB42 and S100B in CSF was also observed.
We did not detect any signs of AB42 in the brain homogenate with ELISA, possibly due to a low concentration of AB42 in the brain of the newborn pigs.
Neither did we detect any signs of aggregation of AB42 in the brain tissue with the optical microscope, however a possible presence of small aggregates of AB42, below the detection limit of an optical microscope, cannot be excluded.
Taking these points into consideration, it is tempting to speculate that the reduction of AB42 in CSF and the negative correlation with S100B after neonatal hypoxia-reoxygenation, could be a sign of aggregation of AB42, which in turn attacks the neurons, triggering a long-lasting process.
In addition, it is an interesting observation that the same cognitive skills which are very often reduced for relatively well-functioning children after perinatal asphyxia are similar to the skills which are influenced in the earliest phases of AD, such as attention and visuospatial skills [23–25].
The moderate negative correlation between AB42 and lactate at end of hypoxia could strengthen the speculation that perinatal asphyxia might inflict neurodegenerative changes, as a study on newborn lambs from 2014 showed a high correlation between lactate 4 hours after asphyxia and histological degeneration of hippocampus 72 hours after asphyxia .
Could the neurons injured after neonatal hypoxia-reoxygenation be more prone to increased oxidative stress in late adulthood than their peers and could this make them more prone to neurodegenerative disorders such as AD?
It would be worthwhile to study whether AB42 and S100B in CSF could represent useful biomarkers at an early stage of brain damage after perinatal hypoxia-reoxygenation.
Limitations of the study
We are aware that a relatively small number of animals were investigated. The pigs were sacrificed 9.5 hours after end of hypoxia, thus there were no long term follow-up.
It would have been highly interesting examining the brain of the pigs with electron microscope and search for possible changes in the neurons. However, to find the regions of interest, when we could not discover any changes in the optical microscope would have been very difficult.
As this is an animal study caution should be taken interpreting it on humans.
To our knowledge, this study is the first to show an association between AB42 in CSF and perinatal hypoxia. Whether or not the reduction of AB42 in CSF after perinatal hypoxia has an etiological basis for adult neurodegenerative disorders needs to be studied with additional experiments and epidemiological studies.
AB42 and S100b are significantly changed in neonatal pigs subjected to severe hypoxia compared to controls, thus they may be valuable biomarkers of perinatal asphyxia.
S1 File. Graphpad-File for the values of LogNSE and LogS100B for each pig.
The authors wish to thank Vivi Stubberud, Aurora Pamplona, Sera Sebastian, Grethe Dyrhaug, Monica Atneosen-Åsegg, Santiago Rivera and Eliane Charrat. Roche Diagnostics supported the study with ELISA kits for investigating S100B in CSF and blood.
The study was funded by Helse-SørØst (South and Eastern Norway Regional Health Authority; Source number: 6051. Project number: 39570.
Conceived and designed the experiments: TB RS ODS. Performed the experiments: TB LP RS. Analyzed the data: TB NB AS LS. Contributed reagents/materials/analysis tools: NB AS. Wrote the paper: TB LP NB AS RS LB LS ODS.
- 1. WHO. World Health Organization. Annual report 2010. 2010.
- 2. Massaro AN, Chang T, Baumgart S, McCarter R, Nelson KB, Glass P. Biomarkers S100B and Neuron-Specific Enolase Predict Outcome in Hypothermia-Treated Encephalopathic Newborns*. Pediatric critical care medicine: a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies. 2014 Sep;15(7):615–22. pmid:24777302. Epub 2014/04/30. eng.
- 3. Gadad BS, Britton GB, Rao KS. Targeting oligomers in neurodegenerative disorders: lessons from alpha-synuclein, tau, and amyloid-beta peptide. Journal of Alzheimer's disease: JAD. 2011;24 Suppl 2:223–32. pmid:21460436. Epub 2011/04/05. eng.
- 4. Molinuevo JL, Blennow K, Dubois B, Engelborghs S, Lewczuk P, Perret-Liaudet A, et al. The clinical use of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: A consensus paper from the Alzheimer's Biomarkers Standardization Initiative. Alzheimer's & dementia: the journal of the Alzheimer's Association. 2014 Aug 20. pmid:25150736. Epub 2014/08/26. Eng.
- 5. Garcia-Ribas G, Lopez-Sendon Moreno JL, Garcia-Caldentey J. [Biomarkers in Alzheimer's disease]. Revista de neurologia. 2014 Apr 1;58(7):308–17. pmid:24677154. Epub 2014/03/29. Biomarcadores en la enfermedad de Alzheimer. spa.
- 6. de Bont JM, Vanderstichele H, Reddingius RE, Pieters R, van Gool SW. Increased total-Tau levels in cerebrospinal fluid of pediatric hydrocephalus and brain tumor patients. European journal of paediatric neurology: EJPN: official journal of the European Paediatric Neurology Society. 2008 Jul;12(4):334–41. pmid:17951083. Epub 2007/10/24. eng.
- 7. Inoue H, Matsushige T, Hasegawa S, Abe A, Iida Y, Inoue T, et al. Elevation of tau protein levels in the cerebrospinal fluid of children with West syndrome. Epilepsy Res. 2012 Nov;102(1–2):8–12. pmid:22831649. Epub 2012/07/27. eng.
- 8. Magnoni S, Esparza TJ, Conte V, Carbonara M, Carrabba G, Holtzman DM, et al. Tau elevations in the brain extracellular space correlate with reduced amyloid-beta levels and predict adverse clinical outcomes after severe traumatic brain injury. Brain: a journal of neurology. 2012 Apr;135(Pt 4):1268–80. pmid:22116192. Pubmed Central PMCID: PMC3326246. Epub 2011/11/26. eng.
- 9. Randall J, Mortberg E, Provuncher GK, Fournier DR, Duffy DC, Rubertsson S, et al. Tau proteins in serum predict neurological outcome after hypoxic brain injury from cardiac arrest: results of a pilot study. Resuscitation. 2013 Mar;84(3):351–6. pmid:22885094. Epub 2012/08/14. eng.
- 10. Zetterberg H, Mortberg E, Song L, Chang L, Provuncher GK, Patel PP, et al. Hypoxia due to cardiac arrest induces a time-dependent increase in serum amyloid beta levels in humans. PloS one. 2011;6(12):e28263. pmid:22194817. Pubmed Central PMCID: PMC3237426. Epub 2011/12/24. eng.
- 11. Mathis G. Rare earth cryptates and homogeneous fluoroimmunoassays with human sera. Clinical chemistry. 1993 Sep;39(9):1953–9. pmid:8375081. Epub 1993/09/01. eng.
- 12. Hardy J, Allsop D. Amyloid deposition as the central event in the aetiology of Alzheimer's disease. Trends in pharmacological sciences. 1991 Oct;12(10):383–8. pmid:1763432. Epub 1991/10/01. eng.
- 13. Karran E, Mercken M, De Strooper B. The amyloid cascade hypothesis for Alzheimer's disease: an appraisal for the development of therapeutics. Nature reviews Drug discovery. 2011 Sep;10(9):698–712. pmid:21852788. Epub 2011/08/20. eng.
- 14. Hansson O, Zetterberg H, Vanmechelen E, Vanderstichele H, Andreasson U, Londos E, et al. Evaluation of plasma Abeta(40) and Abeta(42) as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment. Neurobiology of aging. 2010 Mar;31(3):357–67. pmid:18486992. Epub 2008/05/20. eng.
- 15. Lue LF, Kuo YM, Roher AE, Brachova L, Shen Y, Sue L, et al. Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease. The American journal of pathology. 1999 Sep;155(3):853–62. pmid:10487842. Pubmed Central PMCID: PMC1866907. Epub 1999/09/17. eng.
- 16. Bates KA, Verdile G, Li QX, Ames D, Hudson P, Masters CL, et al. Clearance mechanisms of Alzheimer's amyloid-beta peptide: implications for therapeutic design and diagnostic tests. Molecular psychiatry. 2009 May;14(5):469–86. pmid:18794889. Epub 2008/09/17. eng.
- 17. Bucciantini M, Giannoni E, Chiti F, Baroni F, Formigli L, Zurdo J, et al. Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases. Nature. 2002 Apr 4;416(6880):507–11. pmid:11932737. Epub 2002/04/05. eng.
- 18. Lambert MP, Barlow AK, Chromy BA, Edwards C, Freed R, Liosatos M, et al. Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proceedings of the National Academy of Sciences of the United States of America. 1998 May 26;95(11):6448–53. pmid:9600986. Pubmed Central PMCID: PMC27787. Epub 1998/05/30. eng.
- 19. Pillot T, Goethals M, Vanloo B, Talussot C, Brasseur R, Vandekerckhove J, et al. Fusogenic properties of the C-terminal domain of the Alzheimer beta-amyloid peptide. The Journal of biological chemistry. 1996 Nov 15;271(46):28757–65. pmid:8910517. Epub 1996/11/15. eng.
- 20. Pillot T, Drouet B, Queille S, Labeur C, Vandekerchkhove J, Rosseneu M, et al. The nonfibrillar amyloid beta-peptide induces apoptotic neuronal cell death: involvement of its C-terminal fusogenic domain. Journal of neurochemistry. 1999 Oct;73(4):1626–34. pmid:10501209. Epub 1999/09/29. eng.
- 21. Kecskes Z, Dunster KR, Colditz PB. NSE and S100 after hypoxia in the newborn pig. Pediatric research. 2005 Nov;58(5):953–7. pmid:16183811.
- 22. Blennow M, Savman K, Ilves P, Thoresen M, Rosengren L. Brain-specific proteins in the cerebrospinal fluid of severely asphyxiated newborn infants. Acta paediatrica (Oslo, Norway: 1992). 2001 Oct;90(10):1171–5. pmid:11697430. Epub 2001/11/08. eng.
- 23. van Handel M, de Sonneville L, de Vries LS, Jongmans MJ, Swaab H. Specific memory impairment following neonatal encephalopathy in term-born children. Developmental neuropsychology. 2012;37(1):30–50. pmid:22292830. Epub 2012/02/02. eng.
- 24. van Handel M, Swaab H, de Vries LS, Jongmans MJ. Behavioral outcome in children with a history of neonatal encephalopathy following perinatal asphyxia. Journal of pediatric psychology. 2010 Apr;35(3):286–95. pmid:19542199. Epub 2009/06/23. eng.
- 25. Backman L, Jones S, Berger AK, Laukka EJ, Small BJ. Multiple cognitive deficits during the transition to Alzheimer's disease. Journal of internal medicine. 2004 Sep;256(3):195–204. pmid:15324363. Epub 2004/08/25. eng.
- 26. Aridas JD, Yawno T, Sutherland AE, Nitsos I, Ditchfield M, Wong FY, et al. Detecting brain injury in neonatal hypoxic ischemic encephalopathy: closing the gap between experimental and clinical research. Experimental neurology. 2014 Nov;261:281–90. pmid:25079368. Epub 2014/08/01. eng.